{"filing":{"accession_number":"0001171843-26-005973","cik":"0002027329","ticker":"OPTHF","company_name":"Optimi Health Corp.","form":"6-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"f6k_091026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2027329/000117184326005973/f6k_091026.htm"},"events":[{"id":32568,"run_id":29926,"accession_number":"0001171843-26-005973","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Optimi announces initiation of a Phase 2 clinical trial for psilocybin-assisted therapy for major depressive disorder, authorized by Health Canada and enrolling up to 200 participants—described as \"the largest clinical commitment Optimi has made to date.\" This represents a material strategic and operational milestone in the company's clinical development program, distinct from routine operational announcements. While not fitting a specific named event type (not M\u0026A, not a financial obligation, not a governance change), it is clearly a material operational/strategic development that would affect a reasonable investor's assessment of the company's pipeline and competitive positioning.","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-09-10","form":"6-K","submitted_at":null,"items":[{"id":35768,"accession_number":"0001171843-26-005973","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Optimi announces initiation of a Phase 2 clinical trial for psilocybin-assisted therapy for major depressive disorder, authorized by Health Canada and enrolling up to 200 participants—described as \"the largest clinical commitment Optimi has made to date.\" This represents a material strategic and operational milestone in the company's clinical development program, distinct from routine operational announcements. While not fitting a specific named event type (not M\u0026A, not a financial obligation, not a governance change), it is clearly a material operational/strategic development that would affect a reasonable investor's assessment of the company's pipeline and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:45:42.557920+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35768,"accession_number":"0001171843-26-005973","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Optimi announces initiation of a Phase 2 clinical trial for psilocybin-assisted therapy for major depressive disorder, authorized by Health Canada and enrolling up to 200 participants—described as \"the largest clinical commitment Optimi has made to date.\" This represents a material strategic and operational milestone in the company's clinical development program, distinct from routine operational announcements. While not fitting a specific named event type (not M\u0026A, not a financial obligation, not a governance change), it is clearly a material operational/strategic development that would affect a reasonable investor's assessment of the company's pipeline and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:45:42.557920+00:00","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-09-10"}]}